135 related articles for article (PubMed ID: 37012339)
1. First CRISPR therapy seeks landmark approval.
Kingwell K
Nat Rev Drug Discov; 2023 May; 22(5):339-341. PubMed ID: 37012339
[No Abstract] [Full Text] [Related]
2. [A new method in biotechnology].
Hofmann-Aßmus M
MMW Fortschr Med; 2015 Apr; 157(7):75. PubMed ID: 26012467
[No Abstract] [Full Text] [Related]
3. [CRISPR-Cas system as molecular scissors for gene therapy].
Heinz GA; Mashreghi MF
Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
[TBL] [Abstract][Full Text] [Related]
4. Editing and investigating genomes with TALE and CRISPR/Cas systems: applications of artificial TALE and CRISPR-Cas systems.
Giovannangeli C; Concordet JP
Methods; 2014 Sep; 69(2):119-20. PubMed ID: 25248487
[No Abstract] [Full Text] [Related]
5. CRISPR-Cas9: A revolution in genome editing in rheumatic diseases.
Duroux-Richard I; Giovannangeli C; Apparailly F
Joint Bone Spine; 2017 Jan; 84(1):1-4. PubMed ID: 27825565
[No Abstract] [Full Text] [Related]
6. CRISPR on the Move in 2019.
Barrangou R
CRISPR J; 2019 Feb; 2():1-2. PubMed ID: 31021232
[No Abstract] [Full Text] [Related]
7. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
Cheng X; Fan S; Wen C; Du X
Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
[TBL] [Abstract][Full Text] [Related]
9. [The affair "Crispr-Cas9" or genetically enhanced humanity].
Nau JY
Rev Med Suisse; 2014 Jun; 10(436):1428-9. PubMed ID: 25055481
[No Abstract] [Full Text] [Related]
10. Cas9 immunity creates challenges for CRISPR gene editing therapies.
Crudele JM; Chamberlain JS
Nat Commun; 2018 Aug; 9(1):3497. PubMed ID: 30158648
[TBL] [Abstract][Full Text] [Related]
11. CRISPR Jumps in New Directions.
LeMieux J
CRISPR J; 2019 Dec; 2(6):354-356. PubMed ID: 31860346
[No Abstract] [Full Text] [Related]
12. CRISPR gene therapy shows promise against blood diseases.
Ledford H
Nature; 2020 Dec; 588(7838):383. PubMed ID: 33299166
[No Abstract] [Full Text] [Related]
13. Advances in therapeutic application of CRISPR-Cas9.
Sun J; Wang J; Zheng D; Hu X
Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
[TBL] [Abstract][Full Text] [Related]
14. Meeting Report: German Genetics Society-Genome Editing with CRISPR.
Maier LK; Marchfelder A; Randau L
Bioessays; 2020 Feb; 42(2):e1900223. PubMed ID: 31853989
[No Abstract] [Full Text] [Related]
15. Time To Let CRISPR B.E.?
Barrangou R
CRISPR J; 2019 Apr; 2():67. PubMed ID: 30998099
[No Abstract] [Full Text] [Related]
16. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
Liu W; Yang C; Liu Y; Jiang G
Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
[TBL] [Abstract][Full Text] [Related]
17. CRISPR adaptation in Escherichia coli subtypeI-E system.
Kiro R; Goren MG; Yosef I; Qimron U
Biochem Soc Trans; 2013 Dec; 41(6):1412-5. PubMed ID: 24256229
[TBL] [Abstract][Full Text] [Related]
18. [The revolution of the CRISPR is underway].
Gilgenkrantz H
Med Sci (Paris); 2014 Dec; 30(12):1066-9. PubMed ID: 25537031
[No Abstract] [Full Text] [Related]
19. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.
Song M
Biotechnol Prog; 2017 Jul; 33(4):1035-1045. PubMed ID: 28440027
[TBL] [Abstract][Full Text] [Related]
20. CRISPR Surveillance Turns Transposon Taxi.
Wiegand T; Wiedenheft B
CRISPR J; 2020 Feb; 3(1):10-12. PubMed ID: 32091255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
